Last10K.com

Aldeyra Therapeutics, Inc. (ALDX) SEC Filing 10-K Annual Report for the fiscal year ending Sunday, December 31, 2023

SEC Filings

ALDX Valuations

Intrinsic Value
Financial Stability
Financial Ratios
Insider Trades
Manager Portfolios
Notifications

ALDX Annual Reports

ALDX Quarterly Reports

ALDX Corporate News

Aldeyra Therapeutics, Inc.

HISTORY TOOLS
CIK: 1341235 Ticker: ALDX
Document And Entity Information - USD ($)
12 Months Ended
Dec. 31, 2023
Mar. 06, 2024
Jun. 30, 2023
Cover [Abstract]   
Document Type10-K  
Amendment Flagfalse  
Document Period End DateDec. 31, 2023  
Document Fiscal Year Focus2023  
Document Fiscal Period FocusFY  
Trading SymbolALDX  
Entity Registrant NameALDEYRA THERAPEUTICS, INC.  
Entity Central Index Key0001341235  
Current Fiscal Year End Date--12-31  
Entity Filer CategoryNon-accelerated Filer  
Entity Well-known Seasoned IssuerNo  
Entity Current Reporting StatusYes  
Entity Voluntary FilersNo  
Entity Emerging Growth Companyfalse  
Entity Small Businesstrue  
ICFR Auditor Attestation Flagfalse  
Entity Shell Companyfalse  
Entity Common Stock, Shares Outstanding 58,895,768 
Entity Public Float  $ 483,311,890
Entity Tax Identification Number20-1968197  
Entity Interactive Data CurrentYes  
Document Annual Reporttrue  
Document Transition Reportfalse  
Security Exchange NameNASDAQ  
Documents Incorporated by ReferenceSpecified portions of the registrant’s proxy statement with respect to the registrant’s 2024 Annual Meeting of Stockholders, which is to be filed pursuant to Regulation 14A within 120 days after the end of the registrant’s fiscal year ended December 31, 2023, are incorporated by reference into Part III of this Annual Report on Form 10-K  
Entity Address, Address Line One131 Hartwell Avenue  
Entity Address, Address Line TwoSuite 320  
Entity Address, City or TownLexington  
Entity Address, State or ProvinceMA  
Entity Address, Postal Zip Code02421  
City Area Code781  
Local Phone Number761-4904  
Entity Incorporation, State or Country CodeDE  
Title of 12(b) SecurityCommon Stock, $0.001 par value per share  
Entity File Number001-36332  
Auditor Firm ID243  
Auditor NameBDO USA, P.C.  
Auditor LocationBoston, Massachusetts  
Document Financial Statement Error Correction [Flag]false  

View differences made from one year to another to evaluate Aldeyra Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aldeyra Therapeutics, Inc..

Continue

Assess how Aldeyra Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aldeyra Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2024 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Legal
Revenue
M & A
Mgmt Change
Other
Filter Subcategory:
All
Debt
Expense
Product
Income
Shares
Cash Flow
Geography
Earnings
Other
Inside Aldeyra Therapeutics, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Comprehensive Loss
Consolidated Statements Of Operations
Consolidated Statements Of Stockholders' Equity
Accrued Expenses
Accrued Expenses (Tables)
Accrued Expenses - Schedule Of Accrued Expenses (Detail)
Basis Of Presentation And Significant Accounting Policies
Basis Of Presentation And Significant Accounting Policies (Policies)
Basis Of Presentation And Significant Accounting Policies - Additional Information (Detail)
Cash, Cash Equivalents And Marketable Securities
Cash, Cash Equivalents And Marketable Securities (Tables)
Cash, Cash Equivalents And Marketable Securities - Additional Information (Detail)
Cash, Cash Equivalents And Marketable Securities - Schedule Of Cash And Cash Equivalents (Detail)
Commitments And Contingencies
Commitments And Contingencies - Additional Information (Detail)
Credit Facility
Credit Facility (Tables)
Credit Facility - Additional Information (Detail)
Credit Facility - Schedule Of Long-Term Debt (Detail)
Credit Facility - Schedule Of Principal Payments Incuding End Of Term Charges (Detail)
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements - Schedule Of Assets And Liabilities Measured At Fair Value On Recurring Basis (Detail)
Helio Vision Acquisition
Helio Vision Acquisition - Additional Information (Detail)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Detail)
Income Taxes - Components Of Deferred Tax Assets And Liabilities (Detail)
Income Taxes - Components Of Income Tax Benefit (Detail)
Income Taxes - Summary Of Statutory Tax Rates And Effective Tax Rates (Detail)
Insider Trading Arrangements
Leases
Leases (Tables)
Leases - Additional Information (Detail)
Leases - Schedule Of Future Minimum Payments Under Non-Cancelable Operating Leases (Detail)
Leases - Schedule Of Maturities And Balance Sheet Presentation Of Lease Liabilities (Detail)
Nature Of Business
Net Loss Per Share
Net Loss Per Share (Tables)
Net Loss Per Share - Computation Of Diluted Weighted-Average Shares Outstanding (Detail)
Pay Vs Performance Disclosure
Prepaid Expenses And Other Current Assets
Prepaid Expenses And Other Current Assets (Tables)
Prepaid Expenses And Other Current Assets - Schedule Of Prepaid Expenses And Other Current Assets (Details)
Significant Agreements
Significant Agreements (Additional Information) (Details)
Stock Incentive Plan
Stock Incentive Plan (Tables)
Stock Incentive Plan - Additional Information (Detail)
Stock Incentive Plan - Schedule Of Fair Value Of Employee Stock Purchase Plan Assumptions (Detail)
Stock Incentive Plan - Schedule Of Fair Value Of Stock Option Assumptions (Detail)
Stock Incentive Plan - Schedule Of Stock-Based Compensation Expense (Detail)
Stock Incentive Plan - Summary Of Activity Relating To Restricted Stock Units (Detail)
Stock Incentive Plan - Summary Of Employee Stock Purchase Plan Activity (Detail)
Stock Incentive Plan - Summary Of Stock Option Activity (Detail)
Stock Incentive Plan - Summary Of Stock Option Activity (Parenthetical) (Detail)
Stockholders' Equity
Stockholders' Equity - Additional Information (Detail)
Ticker: ALDX
CIK: 1341235
Form Type: 10-K Annual Report
Accession Number: 0000950170-24-027933
Submitted to the SEC: Thu Mar 07 2024 4:06:42 PM EST
Accepted by the SEC: Thu Mar 07 2024
Period: Sunday, December 31, 2023
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/aldx/0000950170-24-027933.htm